Dignitana AB Stock price

Equities

DIGN

SE0002108001

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Stockholm 07:59:43 2024-03-28 am EDT 5-day change 1st Jan Change
1.99 SEK +6.42% Intraday chart for Dignitana AB +5.29% -8.72%
Sales 2023 86.06M 8.08M Sales 2024 * 120M 11.25M Capitalization 132M 12.38M
Net income 2023 -17M -1.6M Net income 2024 * 3M 282K EV / Sales 2023 1.94 x
Net Debt 2023 13.08M 1.23M Net Debt 2024 * 3.2M 301K EV / Sales 2024 * 1.13 x
P/E ratio 2023
-8.72 x
P/E ratio 2024 *
-
Employees 27
Yield 2023 *
-
Yield 2024 *
-
Free-Float 68.27%
More Fundamentals * Assessed data
Dynamic Chart
1 day+6.42%
1 week+5.29%
Current month+8.15%
1 month+1.53%
3 months+7.28%
6 months-26.02%
Current year-8.72%
More quotes
1 week
1.77
Extreme 1.765
1.99
1 month
1.77
Extreme 1.765
1.99
Current year
1.31
Extreme 1.305
2.15
1 year
1.31
Extreme 1.305
5.00
3 years
1.31
Extreme 1.305
13.15
5 years
1.31
Extreme 1.305
13.15
10 years
1.31
Extreme 1.305
24.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 22-05-18
Director of Finance/CFO 53 22-06-30
Chairman 64 19-12-31
Members of the board TitleAgeSince
Chairman 64 19-12-31
Director/Board Member 61 19-12-31
Director/Board Member 51 20-12-31
More insiders
Date Price Change Volume
24-03-28 1.99 +6.42% 12 214
24-03-27 1.87 +3.89% 19,094
24-03-26 1.8 -2.44% 26,391
24-03-25 1.845 -2.38% 118,491
24-03-22 1.89 0.00% 32,791

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 07:59 am EDT

More quotes
Dignitana AB is a Sweden-based medical technology company. It develops, manufactures and markets a medical device primarily used for scalp cooling in order to eliminate or reduce chemotherapy induced hair loss. The Company focuses on the product DigniCap, which counteracts hair loss during chemotherapy. The product is a cold cap, which when put on the patient's head, lowers the temperature of the scalp. The low temperature reduces perfusion, delivery of blood and metabolism. The reduced blood flow results in a smaller amount of chemotherapy available for uptake in the cells, while the decreased temperature results in less absorption and reduced effects of chemotherapy. These factors together reduce the risk of hair loss. The DigniCap scalp cooling system is patented in Europe, Japan and the United States. It has a subsidiary BrainCool AB, which focuses on producing different models of brain cooling for stroke and cardiac arrest patients.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
  1. Stock
  2. Equities
  3. Stock Dignitana AB - Nasdaq Stockholm